(Q38092136)

28 August 2017

title

The use of raloxifene in osteoporosis treatment (English)

1 reference

28 August 2017

0 references

Patrizia D'Amelio

1

1 reference

28 August 2017

Giovanni Carlo Isaia

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

24 March 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

949-956

1 reference

Clinical characteristics and incidence of first fracture in a consecutive sample of post-menopausal women attending osteoporosis centers: The PROTEO-1 study.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Transmenopausal changes in the trabecular bone structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Molecular determinants of tissue selectivity in estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Cloning of a novel receptor expressed in rat prostate and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

ER beta: identification and characterization of a novel human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Raloxifene use in clinical practice: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

The effect of antiresorptives on bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.782002

10.1517/14656566.2013.782002

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference